Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
99295 trials found · Page 1 of 4965
-
Landmark trial proves mRNA vaccine stops COVID-19
⭐️ VACCINE ⭐️ CompletedThis is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expand…
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated May 29, 2026 14:15 UTC
-
Gene editing offers hope for 'Bubble Boy' disease
⭐️ CURE ⭐️ ENROLLING_BY_INVITATIONBackground: X-linked severe combined immunodeficiency (XSCID) is a rare inherited disorder that affects the immune system. It is caused by a change in the IL2RG gene. Researchers are investigating a new type of gene therapy for people with XSCID. This technique, called base-edit…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ CURE ⭐️
Last updated May 30, 2026 10:36 UTC
-
Can a single injection restore hearing in deaf children? new gene therapy trial begins.
⭐️ CURE ⭐️ Recruiting nowRegeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety of DB-OTO * Det…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: ⭐️ CURE ⭐️
Last updated May 26, 2026 11:09 UTC
-
One-dose antibody slashes RSV hospitalizations in infants
Prevention CompletedThe purpose of this study was to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth …
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated May 30, 2026 10:35 UTC
-
Major malaria vaccine trial shows promise for african kids
⭐️ VACCINE ⭐️ OngoingA Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria
Phase: PHASE3 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated May 29, 2026 14:19 UTC
-
Oxford vaccine trial shows promise against COVID-19
⭐️ VACCINE ⭐️ CompletedA phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.
Phase: PHASE2, PHASE3 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated May 27, 2026 12:02 UTC
-
Oxford COVID-19 vaccine shows promise in early trial
⭐️ VACCINE ⭐️ CompletedA phase I/II single-blinded, randomised, multi-centre study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers aged 18-55 years. The vaccine will be administered intramuscularly (…
Phase: PHASE1, PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated May 29, 2026 14:17 UTC
-
One-Time gene therapy helps babies with rare muscle disease sit and breathe on their own
Disease control CompletedPhase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a biallelic pathogenic mutation of the survival motor …
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
One-Time gene therapy helps babies with fatal muscle disease sit and survive
Disease control CompletedPhase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Gene transfer aims to cure 'Bubble Boy' disease in newborns
⭐️ CURE ⭐️ TerminatedSCID-X1 is a genetic disorder of blood cells caused by DNA changes in a gene that is required for the normal development of the human immune system. The purpose of this study is to determine if a new method, called lentiviral gene transfer, can be used to treat SCID-X1. This meth…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: ⭐️ CURE ⭐️
Last updated May 30, 2026 10:34 UTC
-
Lab-Grown nerve cells injected into spine could restore movement after paralysis
Disease control Not yet recruitingPurpose: This clinical trial is studying an investigational cell therapy called XS228-a lab-made stem cell product designed to help repair damaged nerves in the spinal cord. The goal is to see if XS228 is safe and can improve movement, sensation, and function in people with recen…
Phase: PHASE2 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 30, 2026 10:32 UTC
-
One-Shot gene therapy could transform sickle cell care
Disease control TerminatedThe purpose of the study is to evaluate the efficacy and safety of CTX001 (exa-cel) in adolescent and adult participants with severe sickle cell disease (SCD), βS/βC genotype (HbSC).
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated May 29, 2026 14:16 UTC
-
3-Day malaria cure could save millions from relapses
⭐️ CURE ⭐️ Not yet recruitingCurrent treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a …
Phase: PHASE3 • Sponsor: Menzies School of Health Research • Aim: ⭐️ CURE ⭐️
Last updated May 20, 2026 11:53 UTC
-
Hope for rett syndrome: gene therapy trial launches for toddlers
Disease control Recruiting nowThe primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.
Phase: PHASE3 • Sponsor: Taysha Gene Therapies, Inc. • Aim: Disease control
Last updated May 30, 2026 10:31 UTC
-
Gene therapy could restore hearing in deaf children
⭐️ CURE ⭐️ Recruiting nowThis study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participa…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Euhearing Therapeutics Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated May 27, 2026 11:51 UTC
-
New study aims to cure some HER2+ breast cancers with smart, adaptive therapy
⭐️ CURE ⭐️ Recruiting nowThie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with lo…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated May 29, 2026 14:17 UTC
-
Liver transplant breakthrough: could stem cells end a lifetime of pills?
Disease control Recruiting nowThis clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed…
Phase: PHASE1, PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Could this combo cure hepatitis b in kids?
⭐️ CURE ⭐️ Not yet recruitingThis study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B.
Phase: PHASE4 • Sponsor: Qing-Lei Zeng • Aim: ⭐️ CURE ⭐️
Last updated May 19, 2026 12:01 UTC
-
Gene editing could cure sickle cell and thalassemia without a donor
⭐️ CURE ⭐️ Recruiting nowA promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease. In gene therapy, the investigators introduce new genetic…
Phase: PHASE1 • Sponsor: Daniel Bauer • Aim: ⭐️ CURE ⭐️
Last updated May 30, 2026 10:35 UTC
-
Pig kidney transplant trial offers new hope for kidney failure patients
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transpl…
Phase: PHASE1, PHASE2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:12 UTC